Invasive tests prompted by cancer screening show high real-world complication rate

Reuters Health - 01/01/2021 - In real-world circumstances, procedures such as biopsy indicated by lung-cancer screening with low-dose computed tomography (LDCT) may not go quite as smoothly as indicated by the National Lung Cancer Screening Trial (NLST), according to an updated analysis. As Dr. Ya-Chen Tina Shih told Reuters Health by email, "Our research found that the complication rates of invasive diagnostic procedures following abnormal finding from lung-cancer screening were higher in community setting than the rates reported in clinical trials." The NLST, a trial of screening with low-dose CT compared with chest radiography, showed that the former could further reduce the rate of death from lung cancer. Based on these findings, in 2015 the Centers for Medicare and Medicaid Services began coverage of such screening for beneficiaries who met eligibility criteria. However, say the researchers, a subsequent community-based study by other researchers based o...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 1 January, 20215 January, 2021